Beike Biotechnology Co. Ltd., of Shenzhen, China, said following the recent Chinese Food and Drug Administration acceptance of its investigational new drug application seeking use of human umbilical cord-derived mesenchymal stem cells to treat lupus, the company anticipates approval to move ahead with the treatment by the end of this year.